Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Migrate is an automatic switching service designed for the customer's expenses by providing the cheapest energy deal per year. This new vertical has signed up 200,000+ people till date. Migrate's technology is the best in generating the largest savings of any of the free switching service. Migrate has recurrent annual revenues related to transactional-based price matching websites. Migrate aims to sell the business to an established trade buyer having achiever of 600,000+ users delivring recurring revenues.
days to go:
Expired
investment:
£610,006
Kwikpay is the first app in the UK to make it easy to top up your prepaid mobiles and prepaid services. Kwikpay have relationships with all major UK mobile operators, as well as mobile operators for another 100 countries.
days to go:
Expired
investment:
£168,821
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.
days to go:
Expired
investment:
£49,990
Easily understand and manage all your insurance in one simple app, ready for the digital age. Wrisk is all about transparency and allows customers to see how much they’re currently paying for their insurance, what actions they can take to reduce their risk and purchase the insurance seamlessly from within the app. Wrisk is seeking investment to expand and cater for as many insurance needs as possible.
days to go:
Expired
investment:
£1,044,630
Desuto have developed a support platform that is designed to help simplify professionals work. Desuto's ehealthtracker helps users to choose the best option when making tough decisions about care.
days to go:
Expired
investment:
£55,677
Ziglu is a financial technology entity that allows a user to access both Forex and digital currencies seamlessly. The company permits a user to use any currency via its Mastercard debit card and protects the user's digital currency up to £50,000 against cyber-attacks. Ziglu is authorised by the UK's Financial Conduct Authority (FCA) as an Electronic Money Institution (EMI) and is one of the first companies involved with digital currencies to be registered under the UK’s Anti-Money Laundering Regulations (AMLR). The company has achieved a 94% rating on TrustPilot, offers customers the option to send money via cryptocurrency, and previously raised £5.25 million in seed funding. Ziglu has featured in media entities like Coindesk and Yahoo Finance. It will use 30% of the investment in product development, 60% on user acquisition, and 10% on international expansion initiatives.
days to go:
Expired
investment:
£3,041,878
